Last: | $94.36 |
---|---|
Change Percent: | -0.68% |
Open: | $93.2 |
Close: | $94.36 |
High: | $94.495 |
Low: | $93.15 |
Volume: | 2,338,261 |
Last Trade Date Time: | 04/19/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$94.36 | $93.2 | $94.36 | $94.495 | $93.15 | 2,338,261 | 04-19-2024 |
$92.57 | $92.85 | $92.57 | $92.93 | $92.35 | 1,054,610 | 04-18-2024 |
$93.08 | $93.63 | $93.08 | $93.78 | $92.87 | 1,168,714 | 04-17-2024 |
$93.2 | $92.85 | $93.2 | $93.37 | $92.64 | 1,914,845 | 04-16-2024 |
$94.41 | $94.2 | $94.41 | $94.965 | $94.11 | 1,501,028 | 04-15-2024 |
$93.52 | $94.99 | $93.52 | $95.05 | $93.41 | 2,099,603 | 04-12-2024 |
$94.34 | $94.87 | $94.34 | $94.91 | $93.75 | 1,623,290 | 04-11-2024 |
$94.38 | $94.57 | $94.38 | $94.67 | $94.035 | 2,399,212 | 04-10-2024 |
$95.81 | $95.67 | $95.81 | $95.9 | $95.385 | 1,375,935 | 04-09-2024 |
$95.48 | $95.74 | $95.48 | $96.15 | $95.2499 | 1,535,120 | 04-08-2024 |
$95.79 | $95.3 | $95.79 | $95.93 | $95.13 | 1,916,901 | 04-05-2024 |
$96.89 | $97.25 | $96.89 | $98.205 | $96.54 | 2,544,694 | 04-04-2024 |
$94.37 | $94.45 | $94.37 | $94.88 | $94.175 | 1,168,904 | 04-03-2024 |
$94.41 | $94.64 | $94.41 | $94.64 | $93.92 | 1,468,622 | 04-02-2024 |
$95.87 | $96.83 | $95.87 | $97.055 | $95.445 | 1,258,616 | 04-01-2024 |
$96.73 | $96.28 | $96.73 | $97.2 | $96.15 | 1,524,700 | 03-29-2024 |
$96.73 | $96.28 | $96.73 | $97.2 | $96.15 | 1,524,700 | 03-28-2024 |
$95.88 | $95.5 | $95.88 | $95.9 | $95.27 | 2,432,095 | 03-27-2024 |
$95.27 | $95.5 | $95.27 | $95.56 | $95.07 | 944,216 | 03-26-2024 |
$95.73 | $96.15 | $95.73 | $96.29 | $95.73 | 3,641,761 | 03-25-2024 |
News, Short Squeeze, Breakout and More Instantly...
Novartis AG Company Name:
NVS Stock Symbol:
NYSE Market:
Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings??...
Novartis AG (NYSE:NVS) released data from the ALITHIOS open-label extension study showing sustained efficacy of first-line, continuous Kesimpta ...
2024-04-17 09:30:00 ET Great dividend stocks don't always have particularly high yields. Still, it's nice to see a solid income stock that boasts one that's higher than average. And if this company can reward its shareholders by constantly raising its payouts -- and if it can do so for long...